Metallostasis in Alzheimer’s disease

Scott Ayton, Peng Lei, Ashley I. Bush

PII: S0891-5849(12)01800-X
DOI: http://dx.doi.org/10.1016/j.freeradbiomed.2012.10.558
Reference: FRB11372

To appear in: Free Radical Biology and Medicine

Received date: 6 September 2012
Revised date: 30 October 2012
Accepted date: 30 October 2012

Cite this article as: Scott Ayton, Peng Lei and Ashley I. Bush, Metallostasis in Alzheimer’s disease, Free Radical Biology and Medicine, http://dx.doi.org/10.1016/j.freeradbiomed.2012.10.558

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Metallostasis in Alzheimer’s disease

Scott Ayton#, Peng Lei#, and Ashley I. Bush*

Florey Institute of Neuroscience and Mental Health, University of Melbourne, VIC, 3010, Australia

*Both authors contributed equally to this work.

Scott Ayton (scott.ayton@unimelb.edu.au)
Peng Lei (p.lei@mhri.edu.au)
Ashley I Bush (ashleyib@unimelb.edu.au)

* Correspondence should be addressed to

Ashley I Bush, MD, PhD
Florey Institute of Neuroscience and Mental Health, Level 4 Kenneth Myer Building, University of Melbourne, VIC, 3010, Australia
Phone: +61 3 9035 6532
Fax: +61 3 9035 3103
Email: ashleyib@unimelb.edu.au
Abstract

2012 has been another year where multiple large scale clinical trials for Alzheimer’s disease (AD) have failed to meet their clinical endpoints. With the social and financial burden of this disease increasing every year, the onus is now on the field of AD researchers to investigate alternative ideas in order to deliver outcomes for patients. While several major clinical trials targeting Aβ have failed, three smaller clinical trials targeting metal interactions with Aβ have all shown benefit for patients. Here we review the genetic, pathological, biochemical and pharmacological evidence that underlie the metal hypothesis of AD. The AD-affected brain suffers from metallostasis, or, fatigue of metal trafficking resulting in redistribution of metals into inappropriate compartments. The metal hypothesis is built upon the triad of transition elements: iron, copper, and zinc. The hypothesis has matured from early investigations showing amyloidogenic and oxidative stress consequences of these metals; recently, disease related proteins: APP, tau and presenilin, have been shown to have major roles in metal regulation, which provides insight into the pathway of neurodegeneration in AD and illuminates potential new therapeutic avenues.

Key Words: Alzheimer’s disease; Amyloid; Tau; Copper; Zinc; Iron
Introduction

Alzheimer’s disease: an overview

AD is a slowly progressive neurological disorder, where neurodegeneration is believed to progress 20-30 years before clinical onset [1]. The predominant symptoms of AD are impairment to cognition and profound memory loss, which reflects neuropathology observed in the frontal cortex and hippocampus of the brain. Neurofibrillary tangles (NFT) and neuritic senile plaques (SP) are the two pathological hallmarks that define AD. Tau protein is the major component of NFT [2-8]. β-amyloid (Aβ) was shown to be the major component of SP [9-11]; this peptide is produced by cleavage of amyloid precursor protein (APP) [12-14].

APP processing occurs via two different pathways; the nonamyloidogenic and amyloidogenic pathways. The first cleavage event, by either α-secretase or β-secretase, determines whether Aβ is generated; the proceeding cleavage by γ-secretase determines the species of Aβ to be generated. β-secretase activity is contributed mostly by an integral membrane aspartic protease named β-site APP-cleaving enzyme 1 (BACE1) [15-17]. γ-secretase is a protease complex consisting of several proteins including presenilin (encoded by PSEN1 and 2) which harbours the active site [18-20]. Certain mutations in APP, PSEN1, and PSEN2 genes can cause familial AD [23], and the fact that they are involved with Aβ production highlights the importance of this peptide to AD pathogenesis. For sporadic AD, the most significant risk factor (other than age) is the allelic variation of the APOE gene; individuals harbouring the APOE ε4 allele have the greatest risk of AD [24]. It is still unknown how ApoE participates in AD pathogenesis, but one possibility is through interaction with Aβ [25-27].

Historic and emerging evidence linking Aβ to AD undoubtedly places this peptide at the centre of AD etiopathology [28]. However, as discussed below, Aβ alone is not sufficient, and is not necessary, to progress the disease.

-Age

The biggest risk factor for AD is age[29]. The disease is never evident in the young, even in the young with disease-causing mutations whom over-express Aβ from birth. Aging is also required to observe cognitive loss, pathology and degeneration in transgenic mice engineered to over-express multiple disease causing genes[30-32]. This means that some phenomenon in the process of aging is required to induce Aβ-mediated neurodegeneration and that Aβ expression alone is not a sufficient cause of disease.
Regional specific degeneration

Aβ is produced in all brain regions, and indeed is ubiquitously expressed in the body [33-35]. AD is, however, characterized by discrete and predictable neuronal loss in the temporal lobe, parietal lobe and parts of the frontal cortex and cingulated gyrus [36] while areas such as the visual cortex and cerebellum are spared. It remains unknown why some areas of brain are unaffected by the disease since these areas also produce Aβ. Since Aβ is not sufficient to cause disease in anatomical areas preserved in AD, it is likely that there are factors in the affected areas which are able to either induce Aβ toxicity, or make distinct areas vulnerable to disease.

Failures of Aβ-targeting drugs in large clinical trials

Owing to the extensive evidence linking Aβ to AD, this peptide has been the target of multiple large-scale clinical trials. Drugs have been used to prevent Aβ production (in multiple ways) and antibodies have targeted Aβ for clearance. No drug that aims to lower Aβ has been effective in preventing cognitive decline in patients with AD [37-40]. Some have argued that we have targeted this disease too late in its progression, and we need to start treatment years before symptoms present. Although this maybe the case, the evidence from these trials suggests that Aβ is not causing continued progression of the disease once symptoms begin, and degeneration from this point onward is likely to be resultant from other factors. Targeting Aβ, therefore, is unlikely to be beneficial to symptomatic patients. Degeneration however, continues in patients with symptoms of disease and there is underexplored opportunity to target other factors that are causing degeneration to continue.

Our research group has long argued that fatigue of metal homeostasis in the brain during the aging process causes deleterious metallic reactions in the brain, including the aggregation of Aβ, and may be a major contributor to the expression of AD, and, more importantly, provide a more tractable therapeutic target to ameliorate disease progression.

The involvement of metals in AD: a historic perspective

Aluminium was the first metal linked with neurodegenerative disease. Injecting aluminium into the brain was shown to induce NFTs in animals [41]. Aluminium was shown later to be enriched in AD brains, and specifically in NFTs [42-45] and SPs [46]. Considerable interest in the aluminium hypothesis of AD was generated by a study which showed that aluminium contamination in drinking water increase the risk of AD by 1.5 fold [47]. However, with the
advance in our knowledge of biochemistry of metals and of AD, the aluminium hypothesis was sidelined. Aluminium is a common contaminant of glassware which could have exaggerated the levels measured in NFTs [43]. Furthermore, aluminium has no known biological function and its concentration within the brain is orders of magnitude less than other bonafide biometals that are essential for brain function, and can also induce Aβ and tau aggregation. Therefore, the metal hypothesis of AD now focuses on a triad of transition metals: zinc [48-50], copper [51-53] and iron [54-57]. This review will discuss the biological and pathological roles of these metals and present a hypothesis that metallostasis in AD, or fatigue in how the brain regulates metals, participates in degeneration.

Zinc

Zinc in neurobiology and its homeostasis in the brain

The brain contains the highest concentrations of zinc within the body [58]. Zinc is an essential component of hundreds of enzymes and transcription factors. Within the healthy brain, the majority of zinc is compartmentalized in membrane-bound metalloproteins (predominantly metallothioneins: MTI,II,III), loosely bound zinc within the cytoplasm, and vesicular zinc enriched in synapses. Synaptic transmission releases high concentrations (1-100μM [59-61]) of zinc into the synapse, which represents a major zinc-efflux mechanism of neurons. Synaptic zinc acts as an antagonist to GABAa [62, 63] and NMDA receptors [59, 64, 65], and activates GPR39 [66], which underlies its functional roles in signal transmission.

Although the uptake of zinc in neurons is not completely defined, the Zrt-, Irt-like Protein (ZIP) members (ZIP1-5, 7-15) are thought to be the major uptake mechanism. Zinc uptake can also be mediated by N-methylD aspartate (NMDA) receptor dependent, volatage gated L-type Ca2+ [67], Ca2+ permeable AMPA/kainate channels [68] and Na+/Zn2+ exchangers [69]. Approximately 50% of zinc uptake requires the AD-linked presenilin protein, however the mechanism of how it contributes to zinc uptake is unknown [70].

Intracellular zinc is sequestered or exported by the ZnT protein family. There are eight known ZnT proteins, however ZnT-2,5,7,8 have low expression within the brain. ZnT-1 is found on the plasma membrane and thus differs from the other ZnT proteins which are expressed on intracellular organelles. ZnT-1 exports zinc from neurons and other cells. ZnT-3 is found in granule, pyramidal, and interneuron cells of the hippocampus and this transports zinc into glutamatergic vesicles [71]. ZnT-4 sequesters cytosolic zinc into acidic vesicles [72] while ZnT-6 sequesters zinc in the trans-Golgi network and vesicular compartments [73].
Zinc levels in AD brains

Sustained elevation of zinc is potentially dangerous [74] and has been investigated for its role in AD. However, reporting of zinc levels in AD-affected brains has been inconsistent. Early surveys of brain tissue found no difference in zinc levels between AD and controls [75, 76]. Later studies showed a decrease in zinc levels in the neocortex [77] and in the superior frontal and parietal gyri, the medial temporal gyrus and thalamus [78], and the hippocampus [78, 79]. Conflicting reports have however shown elevated zinc in Alzheimer’s-affected amygdala [77, 80-82], hippocampus [77, 82], cerebellum [77], olfactory areas [81] and superior temporal gyrus [83]. It is unclear why zinc levels have been reported inconsistently over the years, this may relate to methodological issues, for example, tissue fixation which can affect zinc measurement [84]. Simple bulk tissue analyses, however, is unlikely to capture the full evolvement of zinc in AD. More nuanced analysis of the AD-affected brain has shown altered compartmentalization of zinc.

Zinc mislocalization and dysregulation in AD

Our seminal work regarding zinc in the pathogenesis of AD demonstrated enriched zinc levels in amyloid plaque [49]. Further evidence for mis-compartmentalization of zinc in the AD brain was obtained with microparticle-induced x-ray emission tomography which surveyed zinc status in plaque and surrounding neuropil in the amygdala [85]. Using this technique zinc levels in AD neuropil were found to be elevated 2-3 times above that of controls, while plaque contained 3-4 times the amount of zinc compared to the adjacent neuropil. This finding was later corroborated by histochemistry [86], autometallographic tracing [87] and synchrotron-based infrared and X-ray imaging [88]. While there is still debate regarding zinc levels derived from bulk tissue analysis, there is increasing evidence of inappropriate compartmentalization of zinc in AD brains; this is likely to occur by a failure of proteins that control zinc homeostasis.

The cause of this zinc dysregulation in AD remains unknown, but likely involves failure of one or more of these proteins involved in zinc homeostasis. Metallothionein III, which is found on neurons is reduced in AD brains [89, 90], while metallothionein I/II is increased in astrocytes of post mortem AD brains, and preclinical AD brains [91]. ZnT-1 levels are elevated in the amygdala, hippocampus, and inferior parietal lobule and decreased in the superior and middle temporal gyrus of AD affect post mortem brains compared to controls [92]. ZnT-4 and ZnT-6 are both increased in the hippocampus of AD post mortem brains.
while ZnT-3 is decreased in AD-affected medial temporal gyrus, superior occipital gyrus, superior parietal gyrus, superior frontal gyrus [93].

**The role of zinc in AD pathology**

Aβ binds zinc at residues 6-28 [49, 94-96], with up to three zinc ions bound to histidines 6, 13 and 14 [97]. Zinc binding rapidly induces the aggregation of Aβ into insoluble precipitates, which typify AD pathology [49]. The rat and mouse Aβ sequence differs to that of human Aβ by three amino acids which attenuates the affinity for zinc and may underlie why rodents do not develop amyloid pathology [49].

Zinc dysregulation may offer an explanation as to why Aβ deposition is only apparent in AD-affected neocortex but not other areas of the brain, despite its ubiquitous expression. As previously discussed, ZnT-3 loads zinc into glutamatergic synaptic vesicles, and release of high concentrations of labile zinc in the glutamatergic synapse makes it available for interactions with Aβ. To examine the role of synaptic zinc in Aβ deposition, Tg2576 mice (AD mouse model which overexpresses the Swedish mutation of APP) were crossed with ZnT-3 knockout animals. The double mutant exhibited decreased Aβ burden, supporting a role for synaptic zinc in Aβ toxicity [98].

Zinc, therefore, accentuates Aβ toxicity and zinc sequestration into amyloid deposits [49] induces loss of functional zinc in the synapse. Synaptic zinc deficiency is exacerbated in AD by concomitant loss of ZnT-3 expression [85]. Therefore, by two mechanisms labile zinc is made deficient in the brain neuropil in AD. Loss of synaptic zinc likely contributes to cognitive decline in AD since genetic ablation of ZnT-3, which causes loss of zinc in the synaptic compartment, engenders age-dependent cognitive decline in mice [71]. Miscompartmentalization of zinc in AD likely interferes with signal transduction by NMDA and GABA receptors which may underlie why ZnT-3 knockout mice have cognitive dysfunction. A similar loss of labile synaptic zinc in AD, therefore, could exaggerate cognitive decline.

Zinc may also interfere with APP processing and function. Aβ is produced from proteolytic processing, coordinated by a number of secretases which are regulated by zinc. ADAM requires zinc binding for proteolysis [99]. Zinc also increases the synthesis of presenilin 1 [100], however the activity of the γ-secretase complex is inhibited by zinc [101]. Zinc binding directly to Aβ can mask the proteolytic cleavage site [96] thus inhibiting degradation of Aβ by matrix metalloproteases [102].
Zinc may also be involved in tau pathology since the metal is enriched in tangle-bearing neurons [86]. Zinc moderates translation of tau and also modulate its phosphorylation by affecting the activities of glycogen synthase kinase (GSK)-3β, protein kinase B, ERK1/2 and c-Jun N-terminal kinase [103-105]. Zinc can also directly bind to tau monomers with moderate affinity, altering its conformation [106], and can induce both the fibrillization and aggregation of the protein [107].

Copper

Copper in neurobiology

Copper can undergo redox cycling between \( \text{Cu}^{1+} \) and \( \text{Cu}^{2+} \); this ability has made it useful for many biological functions. Some important copper-containing enzymes include:

- Superoxide dismutase: breaks down superoxide radicals into hydrogen peroxide and oxygen
- Cytochrome c oxidase: Complex IV of the mitochondrial electron transport chain involved in electron transport
- Ceruloplasmin (Cp): oxidises \( \text{Fe}^{2+} \) to \( \text{Fe}^{3+} \) which is required for iron export from cells
- Tyrosinase: catalyses melanin and pigment formation

However, the same chemistry that makes copper useful for biology also allows for free radical formation by the Fenton reaction. In this reaction, free copper catalyses the formation of the toxic hydroxyl radical, from physiologically available hydrogen peroxide [108].

The two classic disorders of copper metabolism, Menkes and Willson’s diseases, highlight copper as an essential element required for brain health. Menkes disease is caused by mutations in the ATP7A gene which is expressed in all cells except hepatic cells [109]. In the intestine, ATP7A allows for copper absorption, and in other organs, ATP7A facilitates copper influx into the Golgi apparatus for copper incorporation into proteins as required [110]. Individuals with Menkes disease are copper deficient and exhibit developmental delay, seizures and neurodegeneration [111]. On the other hand, Wilson’s disease is caused by mutations to the ATP7B gene [112]. ATP7B, like ATP7A, is a p-type ATPase that transports copper into the Golgi apparatus; however unlike ATP7A, ATP7B is predominantly expressed in liver. Liver excretes copper in bile; loss of ATP7B function causes copper accumulation in liver [113]. Liver also secretes Cp, the dominant copper binding protein of plasma, and dysfunction of ATP7B causes loss of Cp and copper in plasma, and a build-up of copper in
liver [114]. Over time, excess copper in liver is excreted into the blood where it accumulates in other tissue. The neurological complications of Wilson’s disease include parkinsonism, dementia and psychosis [115]. Too much or too little copper, therefore, is deleterious to brain health.

**Copper dyshomeostasis in AD**

As is the case for zinc, copper is mis-localised in AD brains. Copper levels in the affected regions of AD brains are decreased [82, 116] with enrichment in plaques and tangles [117]. Copper is released into the glutamatergic synaptic cleft, facilitated by ATP7A, at concentration of around 15μM[118, 119]. Within the synaptic cleft copper causes s-nitrosylation of NMDA receptors which inhibits their activation [120, 121]. It is hypothesised that loss of neuronal copper in AD occurs by sequestration of copper into plaques by Aβ.

It is now well established that Aβ interacts with copper. Copper directly binds to the Aβ peptide [122, 123], but the specific binding sites are still a subject of investigation. Aβ1-16 was shown to be the minimal sequence required for copper binding [124] and has often been studied as a model peptide. The binding between Aβ1-16 and copper is pH dependent [125-128]. Between pH 6-7, Aβ1-16 binds to copper at Asp1, His6, and His13/14; when at pH 8, the binding sites of Aβ1-16 shift to His6, His13 and His14 [126]. At pH10 and higher, Asp1, Ala2, Glu3, and Phe4 can also form a complex with copper [127, 129]. Investigations on longer fragments of Aβ, such as Aβ1-28, and full length Aβ, also support the involvement of N-terminal residues, His6, His13 and His14 for Aβ-copper binding [123, 125]. In addition, Tyr10 and Met35 are also suggested to participate in Aβ-copper binding, but with a lower affinity [130, 131]. Aβ1-40 and Aβ1-42 appear to have different binding affinity to Cu(II) when measured by competitive metal capture analysis. The copper binding site of Aβ1-42 has an affinity of logK_{app}=17.2 in contrast to logK_{app}=10.3 for Aβ1-40 [132]. In contrast, mouse Aβ lacks a histidine which significantly reduced its ability to bind to copper [133]. Amylin, a protein implicated in type 2 diabetes, shares 80% homology with Aβ [134]. Amylin interacts with insulin [135], and has also been shown to bind to copper with N-terminal residues (Cys2, Cys7,His18) [136].

Copper modifies Aβ and accelerates its aggregation. Aβ purified from human plaques contains less histidine residues and tyrosine residues, which has been explained by copper-mediated oxidation [137]. Copper promotes dityrosine cross-linking of Aβ, which is
suggested to act as a seed to accelerate Aβ aggregation [138, 139]. The copper induced Aβ oligomer was found to contain a membrane-penetrating structure with histidine bridging[140, 141], highlighting the importance of histidine in the copper-Aβ interaction[141, 142]. Copper binding initiates [143], and induces rapid Aβ aggregation [52]. Unlike zinc, the copper-mediated Aβ aggregation forms oligomers rather than fibrils, which is not recognized by ThT[144-146].

The copper-Aβ complex has been shown to exhibit cytotoxic properties. Aβ toxicity in cell culture is partially dependent on copper [147]. Copper chelation, or competitive binding, ameliorates Aβ- induced cell death in cell culture [148, 149]. Others showed that copper-mediated Aβ toxicity is more pronounced with oligomers prepared from the Aβ_{1-42} peptide, rather than the Aβ_{1-40} species [150]. The mechanism for copper-Aβ toxicity is still a matter of debate, but one possibility involves inhibition of human cytochrome c oxidase [151]. In addition, oxidative stress is also implicated in copper-Aβ toxicity since in vitro studies showed that copper and Aβ can generate hydrogen peroxide via a catalytic cycle[53, 152, 153]. In accordance with copper-Aβ binding, histidine and methionine residues of Aβ are suggested to be crucial for exerting Aβ’s toxic effects [139, 141, 142].

APP also interacts with copper. In addition to the Aβ segment of the protein, copper binds to APP between residues 142-166 [154-156] and it catalytically reduces copper (II) to copper (I) [51]. APP knockout primary cortical neurons are susceptible to copper-induced toxicity, but copper uptake is not affected [154]. Copper promotes APP internalization [157], and copper deficiency promotes Aβ secretion, but not APP cleavage [157]. Therefore, APP may not directly influence copper homeostasis, but inappropriate interaction with copper may be neurotoxic.

Tau phosphorylation and aggregation can also be induced by copper. Certain fragments in the four-repeat microtubule-binding domain of tau (residues 256-273, 287-304, and 306-336) were shown to aggregate in the presence of copper in vitro [158-160]. Microtubule-binding domain residues 287-293 and 310-324 of a 198 amino acid fragment of tau have been shown by NMR to bind copper [161]. Copper binding to tau induces hydrogen peroxide production in vitro [162], while NFTs have also been shown to bind copper in a redox-dependent manner, acting as a source for ROS within the neuron [163]. Chronic copper exposure induces tau hyperphosphorylation and promotes tau pathology in a mouse model of AD [164]. The copper-induced phosphorylation of tau is suggested to be mediated by abnormal Cdk5
activation. However, drugs that deliver copper to the cell have been shown to reduce tau phosphorylation in the APP/PS1 mouse model of AD, possibly through the inhibition of GSK-3 [165].

Iron

Iron biology

Iron is the most abundant element on the Earth [166]. It is hypothesized that the early chemistry of life occurred on mineral sources rich in ferrous iron, sulphide and hydrogen [167], which are fundamental for energy metabolism in biology. Iron is a transition element that can exist in oxidation states from -2 to +8, but in biological systems only ferrous (Fe²⁺) and ferric (Fe³⁺) states exist. The cycling between Fe³⁺ to Fe²⁺ is utilized in biology for various electron transfer (redox) reactions essential to life. However, this same chemistry can allow for deleterious reactions with oxygen such as the Fenton reaction where H₂O₂ is catalysed by iron to OH⁻ [168] which is a source of oxidative stress [169].

A number of biological processes require iron, including electron transfer reactions [170, 171], transport of oxygen [172], regulation of protein expression [173, 174], cell growth [175] and differentiation [176]. In the brain, iron is involved in development [177], neurotransmitter systems [178], myelination [179] and is required for a number of iron-dependent enzymes [180-182]. Iron is therefore tightly regulated by multiple proteins in the cell, to utilise the element for various functions and to protect against toxicity.

Iron levels in AD

Elevated iron in AD brains was first reported in 1953 [183] and shown to be associated with SP. This initial finding has later confirmed by multiple techniques [57, 184-188]. Iron is enriched in both NFT [54] and SP [183], with the concentration in the latter estimated to be three times that of the normal neuropil level [117]. Iron accumulation occurs in AD cortex, but not cerebellum [56, 189], consistent with the anatomical profile of neurodegeneration in AD. The iron storage protein ferritin binds most iron within the brain [185], and this protein is increases with age and in AD [190]. The iron accumulation in AD could result from a failure of the iron regulatory system, or dysfunctional iron regulating proteins; which is explored below.

Iron regulation in the brain
Transferrin (Tf), which is produced within the brain by oligodendrocytes [191], is the extracellular iron transporting protein which exchanges iron between cells. Iron-bound Tf (holo-Tf) binds to the transferrin receptor (Tfr) expressed on the cell surface [192]. This Tf/Tfr complex is endocytosed [193], where iron is reduced to its ferrous state by an unknown ferrireductase. Ferrous iron is then able to pass through the endosomal membrane via DMT1 and the imported iron assimilates with a labile iron pool (LIP) in the cytosol [194, 195]. Iron within the LIP is available for incorporation into iron-binding proteins, notably ferritin, the iron storage protein [196]. Excess iron is able to exit the cell by ferroportin (Fpn)[197, 198]. Fpn channels ferrous iron though the plasma membrane [199], however, a ferroxidase partner enzyme is required for iron to be released from the cell. Ferrous iron presented on the cell surface by Fpn is available for uptake by extracellular Tf. Tf, however, has a low affinity for ferrous iron and thus iron requires oxidation by a ferroxidase for removal from the cell by Tf. Ceruloplasmin is the classic ferroxidase [200, 201], but this protein it is not expressed in neurons [202]. Recently, AD-associated APP was identified as the analogous neuronal ferroxidase [56]. APP knockout mice exhibit iron accumulation in brain and peripheral tissues and loss of APP ferroxidase activity in AD brain is coincident with iron retention in the tissue [56].

We recently showed that iron-export capability of APP requires tau [203]. Tau has been implicated in axonal transport [204], and binds APP [205]; loss of tau in mice causes age-dependent iron accumulation [203]. In tau knockout primary cortical neurons, APP was inappropriately trafficked and not present on the extracellular surface where it acts as a ferroxidase. Furthermore, the iron accumulation seen in tau knockout neurons can be restored by supplement of sAPP695α.

**Iron dysregulation in AD**

Iron elevation in AD brains could be caused by disturbance of the iron regulatory system; indeed a number of iron associated proteins have an altered expression profile in AD. Ferritin has been reported to be elevated in AD and co-localizes with SP [57]. Tf, normally expressed solely by oligodendrocytes, is also expressed in astrocytes in the AD brain [57], and was found to be increased in frontal cortex of AD [206]. DMT1 levels are is increased in the cortex and hippocampus of an AD transgenic model, but its status in AD brains is unknown [207]. Lower Cp expression was found in AD brains [208] as well as its ferroxidase activity in plasma [209]. The amount of APP protein isn’t significantly changed in AD cortex, but its ferroxidase activity is significantly reduced [56]. Soluble tau protein level is also reduced in
AD brains compared to control brains [210-215]. Taken together, it is likely that the iron accumulation observed in AD is a result of multiple failures in its regulatory proteins.

Genetic factors could also increase the susceptibility to iron burden in AD. Tf variant C2 is weakly associated with AD-risk [216-221]. Mutations in the hemochromatosis gene (H63D and C82Y; which cause iron retention in peripheral tissues in affected patients), were also found to be associated with AD-risk [222-224], possibly by interacting with the ApoE gene [225-227] to synergistically increase AD risk [218, 228-230]. These two genes were also found to modify the brain iron levels and memory in a healthy aging study [231]. However, the links between Tf and the hemochromatosis gene with AD was not confirmed in a recent large-scale GWAS [232, 233].

**A role for iron in AD pathogenesis**

It is hypothesized that the iron burden in AD contributes to oxidative stress in the tissue and can also cause the aggregation of neurodegenerative disease-linked proteins. Iron content is enriched around the SP region [187, 234] and iron promotes Aβ aggregation *in vitro* [235], which is prevented by iron chelation [236]. Iron aggregated Aβ is toxic to cultured cells [237, 238] which was suggested to be mediated by ROS [55], by Fenton chemistry [239], or the activation of Bcl-2 related apoptosis pathway [240]. The redox activity of the iron- Aβ interaction is suggested to facilitate iron binding to His6, His13, and His14 of Aβ [142, 241].

Iron also binds to tau. In fact, an early purification procedure of tau employs an iron-chelating affinity chromatography column [242, 243], clearly indicating binding between tau and iron. Binding of Fe(III), but not Fe(II), induces an aggregation of hyperphosphorylated tau that can be reversed by reducing Fe(III) to Fe(II) [244] or with iron chelators [245]. Within the brain, iron enrichment co-localizes with NFTs in AD and in neurodegeneration with brain iron accumulation (NBIA) [54, 246]. NFTs bind iron which acts as a source for ROS generation within neurons [54, 163]; this can be abolished by iron chelation [247].

Iron has also been shown to affect the phosphorylation status of tau. Treatment of Fe(III) to hippocampal neuron culture resulted in a decrease in tau phosphorylation [248], which corresponded with a decrease CDK5 activity. Conversely, Fe(II) treatment was shown to induce tau phosphorylation [249, 250], without inducing aggregation of the protein. Iron-mediated tau phosphorylation may be caused by up-stream activation of the Erk1/2, MAPK pathway [251, 252].

**Metal hypothesis based AD therapeutics**
A disease modifying therapy for AD has been the subject of extensive research and investment. Unfortunately for patients and families, several large-scale phase III trials have failed to reach their clinical endpoints [37-40]. Reducing Aβ levels within the brain, by inhibiting its production or by removing it with immunotherapy, have been the approaches most extensively investigated so far. It is possible that Aβ is too up-stream in the disease process for a drug to alter disease progression in symptomatic patients, and these same drugs might be more efficacious if treatment commenced years before disease-onset. However, there is of course some process occurring within the AD-afflicted brain that is causing it to deteriorate after symptoms present; but evidence from these failed drug trials would suggest that this process does not involve Aβ. Given that targeting Aβ in multiple ways has so far failed to confer clinical benefits, there is a need to target other, more tractable, pathways in the disease.

**Clioquinol and PBT2**

5-chloro-7-ido-quinolin-8-ol (Clioquinol) is a derivative of 8-hydroxyquinoline that was wildly used as an anti-parasitic agent for intestinal amebiasis in 1930-1970s. The drug was withdrawn from the worldwide market in 1985, due to a speculated severe side-effect, subacute myelo-optico-neuropathy (SMON), only observed in Japan [253, 254], although this association has been disputed [255]. Later, clioquinol was found to act as moderate chelator of iron, copper and zinc, and it is this activity for which the drug is now best characterized. Oral treatment of clioquinol for 9 weeks in an AD mouse model reduced brain Aβ deposition by 40% [255], while another study showed that clioquinol rescued memory impairment [256]. Clioquinol has been shown to modulate copper efflux activities of APP [257], inhibit Aβ oligomer formation [258, 259], and prevent Aβ-injection induced cell loss [260]. A Phase II clinical trial [261] and a case study [262] reported improvement in cognitive outcomes for patients with AD, however complications with large scale manufacturing of the compound have hindered further exploration for its use in AD.

Clioquinol has also been explored in animal models of other neurodegenerative diseases. Clioquinol protected against dopamine depletion and nigral neuron loss in mice administered the PD toxin, MPTP [263] and tau knockout mice which exhibit an age-dependent PD phenotype [203]. Chronic treatment of clioquinol to transgenic Huntington’s mice (R6/2) reduced huntingtin expression and aggregation, prevented striatal atrophy and motor impairment of the mice, and extended their lifespan [264]. Clioquinol was also shown to...
attenuate the effects of general aging. CLK-1 (also known as COQ7), a mitochondrial hydroxylase required for biosynthesis of ubiquinone [265, 266], was shown to be involved in a molecularly defined, and evolutionarily conserved, aging pathway [267-270]. Treatment with clioquinol in cell culture, nematodes, and mice, showed reductions in CLK-1 protein levels and delayed aging in these models, indicating a protective effect of clioquinol against general aging [271]. This effect is possibly mediated by iron since addition of ferrous iron blocked the protective effect of clioquinol [271]. However, toxic effects of clioquinol were reported by some groups [272-274].

Clioquinol has been well studied, but the precise mechanism of action of the drug is unknown. Therapeutic effects of clioquinol have often been attributed to its chelation of copper and zinc [257, 275-277]. However, the affinity of clioquinol for copper and zinc is moderate (Kd_{Cu} is 1.2 x10^{-10} M, Kd_{Zn} is 7x 10^{-6} M) [278], and no in vitro data has demonstrated a reduction in copper and zinc levels in the brain of clioquinol-treated animals [255, 279, 280]. More recently, clioquinol has been shown to act as an ionophore which redistributes copper and zinc into the cell [255, 280-284]. In addition, clioquinol is hypothesized to confer neuroprotection by iron chelation, as iron binds to clioquinol [285-287], and a number of the reported beneficial effects of clioquinol are iron-dependent [239, 263, 267, 288, 289]. In addition, clioquinol can affect the PI3K pathway [290-292] which up-regulates matrix metalloprotease activity to promote Aβ degradation [290].

A second generation 8-hydroxyquinoline derivative, PBT2, showed even greater therapeutic effects on an AD mouse model [281] as well as a Phase II clinical trial [293, 294]. The proposed mechanism for neuroprotection of this drug is, by acting as a copper-zinc ionophore, redistributing copper and zinc inside the cell which induces inhibitory phosphorylation of the α- and β-isoforms of glycogen synthase kinase 3 and subsequently lowering Aβ levels [284].

**bis(thiosemicarbazone) ligands**

Given that the mechanisms of action for both clioquinol and PBT2 likely involve its copper ionophore activity, copper-containing bis(thiosemicarbazone) ligands have been explored for their potential to treat AD. One prototype, Cu^{II}GTSM, delivers copper into neurons [295] and has been show to lower Aβ levels in cell culture [295], restore cognitive performance of APP/PS1 mice in the Y-maze, which reflected changes in GSK3β activity, phosphorylated tau, and Aβ levels within the brain [296]. Another prototype, Cu^{II}ATSM, is more stable and does not release copper within the cell; this compound has not been shown to be beneficial in
the APP/PS1 mouse model [296]. However, Cu\textsuperscript{II}ATSM has been shown to confer protection in four independent mouse models of PD, possibly by inhibiting peroxynitrite-driven toxicity [297].

**Iron chelators**

APP has an iron responsive element that induces translation of the protein in high iron environments [173]. Therefore, containing pro-oxidant iron accumulated in the AD afflicted brain by iron chelation likely has the added benefit of reducing A\textsubscript{β} production. Indeed, the iron chelators, (-)-epigallocatechine-3-gallate and M-30 have been shown to reduce APP expression in cultured cells [298, 299]. The classic iron chelator, deferoxamine, inhibits amyloidogenic APP processing in cultured cells and in APP/PS1 mice, which attenuated A\textsubscript{β} burden within the brain and reversed spatial memory impairment. Intramuscular injection of deferoxamine was tested in a single-blind clinical trial of 48 probable AD patients over a 24 month period [300]. The trial was enacted because deferoxamine also binds aluminium, which the researchers were attempting to target. Over the 24 month period, treatment reduced the rate of decline by half compared to the non-treatment group. Although this trial was published in 1991, iron chelation remains an underexplored avenue to prevent decline in AD patients.

**Conclusions**

Over the past 25 years the AD field at large has understood the disease to be manifestation of abnormally generated toxic species of A\textsubscript{β} and tau, however targeting these species pharmacologically has not conferred benefit to patients so far [37-40]. After well publicized failures of large scale clinical trials, it seems that our field needs an alternative direction. As reviewed here, the role of metals in AD has received extensive investigation. Pathological, biochemical, pharmacological and genetic evidence point to a role for loss of metalostasis in the pathogenesis of disease; however where in the pathway of neurodegeneration metal fatigue occurs is only beginning to be elucidated. It has long been known that metals modulate the aggregation properties of degenerative disease-linked proteins. More recently, the same disease-linked proteins: APP[56], tau[203], and presenilin[70], have been shown to be major players in brain metal homeostasis. It is not of coincidence then, that loss of function of these disease-associated (and now metal-associated) proteins coincides with altered metal compartmentalization in the AD-affected brain [49, 85]. This new data might signify a role for metals more upstream in the disease process than previously thought, and
might provide new targets for pharmacotherapy. In three small scale clinical trials attempted so far, drugs that target metals have shown positive outcomes for patients[261, 293, 294, 300]. Regardless of where metal fatigue occurs in the pathway of AD pathogenesis, targeting metals likely represents a tractable avenue for an AD disease modifying therapy and approaches targeting metals warrant investigation in large scale clinical trials.

Acknowledgement

Supported by funds from the Australian National Health & Medical Research Council (NHMRC) and Operational Infrastructure Support Victorian State Government.
**Figure Legend**

**Figure 1.** Metallostasis in AD. Alzheimer’s disease is complicated by fatigue of metal transport mechanisms, which causes redistribution of metals into inappropriate compartments, leading to neurodegeneration. **Zinc:** In health, zinc is transported by ZIP and ZnT proteins and is required for the function of metallothionein and SOD. ZnT3 loads zinc into exosomes where it modulates synaptic neurotransmission by inhibiting NMDAR. In AD, exchangeable synaptic zinc is limited because of reduced ZnT3 levels, and zinc is sequestered into amyloid plaque. **Copper:** In health, copper is transported by CtR1 and ATP7a proteins and is required for the functioning of SOD and metallothionein. In AD, copper is depleted intraneuronally while it is sequestered into amyloid deposits. **Iron:** In health iron is imported by Tfr-DMT1 endocytic pathway and is exported via ferroportin. APP is a ferroxidase which is required for iron release from neurons and tau is involved in the trafficking of APP to the neuronal surface. In AD, tau is phosphorylated and APP is inhibited, leading to intraneuronal iron accumulation.
References


[125] Syme, C. D.; Nadal, R. C.; Rigby, S. E. J.; Viles, J. H. Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence,


[135] Cui, W.; Ma, J.-w.; Lei, P.; Wu, W.-h.; Yu, Y.-p.; Xiang, Y.; Tong, A.-j.; Zhao, Y.-f.; Li, Y.-m. Insulin is a kinetic but not a thermodynamic inhibitor of amylin aggregation. *Febs J* **276:**3365-3371; 2009.


Highlights

- Alzheimer’s disease is complicated by inappropriate compartmentalization of metals
- Zn and Cu are sequestered into plaque while intraneurally these metals are depleted
- Dysfunction of APP and tau engender intraneuronal iron accumulation
- Drugs that modulate metals have shown promise in 3 clinical trials for AD
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Ayton, S; Lei, P; Bush, Al

Title:
Metallostatics in Alzheimer's disease

Date:
2013-09-01

Citation:
Ayton, S; Lei, P; Bush, Al, Metallostatics in Alzheimer's disease, FREE RADICAL BIOLOGY AND MEDICINE, 2013, 62 pp. 76 - 89

Persistent Link:
http://hdl.handle.net/11343/43937